Tirzepatide denied due to quantity / dose limits by Anthem?

Anthem's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Applies Quantity Limits to Tirzepatide

Quantity-limit (QL) denials for tirzepatide occur when the amount prescribed — whether the number of pens, the dosing frequency, or the supply duration — exceeds the quantity Anthem's formulary allows per fill or per coverage period. Anthem sets quantity limits based on its interpretation of the FDA-approved dosing schedule, and requests that exceed those limits require a separate exception or PA. This is among the more straightforwardly appealable denial types when the prescriber can document a clinical rationale for the requested quantity.

Common triggers: the prescriber titrated the patient to a higher dose and the quantity per fill increased accordingly; the patient needs a 90-day supply but the limit is set for 30; or the patient requires more frequent administration than the default QL assumes.

## Your Federal Appeal Rights

• ACA §2719 / External Review: After exhausting Anthem's internal appeals, you may request external review by a certified IRO. Verify the exact request deadline — typically around four months from the final internal denial — from your denial letter.
• ERISA §503 Full-and-Fair Review: ERISA plans must disclose the quantity-limit standard applied and allow you to submit clinical evidence supporting the requested quantity.
• Expedited Review: If treatment is ongoing and interruption poses clinical risk, request expedited review in writing simultaneously with the standard appeal.

## Appeal Timeline

1. Request a copy of Anthem's formulary quantity-limit criteria for tirzepatide. 2. Have the prescriber document the clinical rationale for the prescribed quantity before filing. 3. File the internal appeal within the timeframe stated on your denial letter; internal decisions are typically required within 30 days (pre-service). 4. If denied internally, request IRO external review before the deadline in the final denial.

## Documentation to Gather

• Prescriber letter addressing quantity: A letter explaining the specific clinical reason the prescribed quantity is appropriate — for example, the patient has been titrated per the FDA-approved prescribing information and the current dose corresponds to the requested supply.
• Current dose and titration record: Chart documentation showing the dose history and the prescriber's rationale for the current dose level, referencing the FDA-approved prescribing information as the basis for the titration schedule.
• Diagnosis and treatment response: Chart notes and any relevant labs demonstrating the patient's clinical response and the therapeutic basis for continuing at the prescribed quantity.
• FDA prescribing information: The current label for tirzepatide showing the approved dosing and titration schedule, to demonstrate that the requested quantity is consistent with approved use.

## Criteria-Mapping Structure

Anthem's quantity-limit exception criteria will specify what clinical justification is required to exceed the default limit. Obtain that criteria document and map each requirement to a specific piece of chart evidence or prescriber attestation. Where the prescribed quantity reflects a titration step described in the FDA-approved label, that alignment should be made explicit in the appeal letter. Quantity-limit appeals that clearly tie the requested supply to the approved dosing schedule — with no unsupported numbers added — tend to perform well at external review.